



Cyclobutane Diamine Scaffold

Introduction


Cyclobutane-1,3-diamine is a highly effective small-molecule scaffold, offering both conformational rigidity and optimized metabolic stability.^{1,2} Notably, Pfizer's Abrocitinib, a *cis*-cyclobutane-1,3-diamine derivative, recently received FDA approval for treating atopic dermatitis (eczema).³ Over the past few years, our library of cyclobutane diamine compounds has expanded significantly, incorporating numerous spirocyclic structures to enhance the physicochemical properties.



inhibitor of mucosa-associated lymphoid tissue lymphoma translocation protein 1
WO 2026/003039
Janssen




inhibitor of interleukin-1 receptor-associated kinase 4
WO 2026/005537
Daewoong



inhibitor of phosphoinositide 3-kinase alpha
WO 2025/237374
Wigen



Case study




Abrocitinib (PF-04965842)
inhibitor of Janus kinase 1
FDA approved 2022 against atopic dermatitis
Pfizer

IC₅₀ (JAK1) 0.03 μM
IC₅₀ (JAK2) 0.80 μM
=> selective for JAK1

J. Med. Chem. **2018**, *61*, 1130



We offer: over 100 cyclobutane 1,3-diamines from stock on 5-10 gram scale



References

1. S. Schiesser et al. *Eur. J. Med. Chem.* **2022**, *227*, 113925.
2. D. Freeman et al. *J. Med. Chem.* **2023**, *66*, 15629.

3. M. Vazquez et al. *J. Med. Chem.* **2018**, *61*, 1130.



Search & Buy on-line at [EnamineStore.com](https://www.enamine.net)
Look for more at [Chem-Space.com](https://chem-space.com)

BB@enamine.net, www.enamine.net

